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Human cortical somatosensory evoked potentials (SEPs) allow an accurate investigation
of thalamocortical and early cortical processing. SEPs reveal a burst of superimposed early
(N20) high-frequency oscillations around 600Hz. Previous studies reported alterations of
SEPs in patients with schizophrenia. This study addresses the question whether those
alterations are also observable in populations at risk for developing schizophrenia or
bipolar disorders. To our knowledge to date, this is the first study investigating SEPs in a
population at risk for developing psychoses. Median nerve SEPs were investigated using
multichannel EEG in individuals at risk for developing bipolar disorders (n = 25), individuals
with high-risk status (n = 59) and ultra-high-risk status for schizophrenia (n = 73) and a
gender and age-matched control group (n = 45). Strengths and latencies of low- and
high-frequency components as estimated by dipole source analysis were compared
between groups. Low- and high-frequency source activity was reduced in both groups
at risk for schizophrenia, in comparison to the group at risk for bipolar disorders. HFO
amplitudes were also significant reduced in subjects with high-risk status for schizophrenia
compared to healthy controls. These differences were accentuated among cannabis
non-users. Reduced N20 source strengths were related to higher positive symptom load.
These results suggest that the risk for schizophrenia, in contrast to bipolar disorders,
may involve an impairment of early cerebral somatosensory processing. Neurophysiologic
alterations in schizophrenia precede the onset of initial psychotic episode and may serve
as indicator of vulnerability for developing schizophrenia.
Keywords: somatosensory evoked potentials, schizophrenia, high-frequency oscillations, risk, thalamus
dysfunction, cannabis
INTRODUCTION
Schizophrenia and bipolar disorders have been considered as
two distinct disorders since Emil Kraepelin (1856–1926) divided
psychotic illness into two diagnostic categories (Craddock and
Owen, 2005). However, schizophrenia and bipolar disorders
have a number of clinical and epidemiological features in com-
mon. Following Griesingers (1817–1868) unitary concept of
psychosis called “Einheitspsychose,” it has been suggested that
psychotic symptoms may be distributed along a continuum
(Crow, 1986). To date it is still unclear whether or not these
two major psychoses are distinct entities or if bipolar disorder
and schizophrenia patients share, e.g., common neurophysio-
logic dysfunction (Alaerts and Del-Favero, 2009; Kurnianingsih
et al., 2011; Whalley et al., 2012; Redpath et al., 2013). Both
distinctive and similar patterns of brain structural abnormality
were observed in patients with schizophrenia vs. bipolar disorders
(McDonald et al., 2004; Murray et al., 2004).
The thalamus is considered to play a crucial role in the
pathophysiology of psychiatric illnesses such as schizophrenia
(Andreasen, 1997) and mood disorders (Soares and Mann,
1997). The thalamus forms a variable gate of access for sen-
sory information to reach the cerebral cortex (McCormick
and Bal, 1994). Dysfunctional cortico-striato-thalamic connec-
tions and abnormal thalamocortical connections associated with
schizophrenia were widely demonstrated (Carlsson and Carlsson,
1990; Andreasen, 1997; Jones, 1997; Woodward et al., 2012).
Furthermore, schizophrenic patients show anatomic (Andreasen
et al., 1994; Gur et al., 1998; Portas et al., 1998; Staal et al.,
1998; Hazlett et al., 1999; Ettinger et al., 2007) and metabolic
(Szechtman et al., 1988; Siegel et al., 1993; Buchsbaum et al.,
1996; Holcomb et al., 1996; Kim et al., 2000) thalamic alter-
ations. In contrast to this, no abnormalities in thalamic size
have been found in persons with bipolar or unipolar affec-
tive disorders (Caetano et al., 2001; Mamah et al., 2010).
Nonetheless, functional and neurochemical abnormalities in
this brain region have been reported for individuals with
bipolar disorders (Buchsbaum et al., 1997; Deicken et al.,
2000).
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Alterations of preattentive sensory gating as reported in neu-
rophysiological studies emphasize the central role of the thalamus
in the regulation of cortical input. The prepulse inhibition has
been shown to be abnormal in patients with schizophrenia and
their relatives (for a review, see Braff, 2010). The findings are
not equally consistent for patients with bipolar disorder (Thaker,
2008). However, two studies reported an abnormal prepulse inhi-
bition in patients with bipolar disorder (Perry et al., 2001) and
their first-degree relatives (Giakoumaki et al., 2007), whereas
Carroll et al. (2007) found no difference in prepulse inhibition
between bipolar patients and healthy controls.
Despite their advantageous high temporal resolution, electro-
physiological studies of possible thalamocortical dysfunction in
schizophrenia or bipolar disorder other than the startle response
are rare. Later evoked potential phenomena have been studied
more often than early ones, i.e., occurring within 50ms after
stimulus application (Shagass et al., 1977). However, early evoked
potentials are less susceptible to changes by uncontrollable factors
such as, e.g., attention, and their underlying neurophysiology is
better understood than that of the later potentials (Shagass et al.,
1977; Buchner et al., 1995).
Thalamocortical and early cortical processing can be investi-
gated accurately with advanced analysis of human median nerve
somatosensory evoked potentials (SEPs) (Shagass et al., 1977;
Lehtonen, 1981; Buchner et al., 1995): SEPs of the median nerve
show a brief oscillatory burst with low amplitudes (<500 nV)
and high frequency (∼600Hz) which can be isolated with high-
pass filtering. These high-frequency oscillations (HFOs) underlie
the primary cortical low-frequency responses represented by a
parietal negativity peak component ∼20ms after stimulation,
i.e., the N20 (Yamada et al., 1988). Functional dissociation of
these two evoked responses indicates different origins for the
low- and high-frequency SEP-components (Emerson et al., 1988;
Yamada et al., 1988; Klostermann et al., 1998, 1999; Hashimoto
et al., 1999; Gobbele et al., 2000, 2004; Halboni et al., 2000).
The N20 is mainly generated by excitatory postsynaptic poten-
tials in Brodman area 3b pyramidal cells (Allison et al., 1991). The
generators of HFO have been proposed as the thalamus, the thala-
mocortical fibers or postsynaptic activities in the primary sensory
cortex (for a review see Curio, 2000). Early and late HFOs, i.e., the
wavelets before and after the peak latency of the N20 as the initial
cortical response, have been supposed to be separate since these
two components differ in their responsiveness to various modu-
lations (Ozaki et al., 2001; Ritter et al., 2008). The early part of the
HFOs is presumably generated from action potentials of thalam-
ocortical fibers (Klostermann et al., 1999; Curio, 2000; Gobbele
et al., 2004). There remains a controversy on the generation of the
later part of somatosensory HFOs. Pyramidal “chattering” cells
(Gray and McCormick, 1996), cortical fast-spiking inhibitory
interneurons (Hashimoto et al., 1996) and thalamocortical relay
cells (Curio, 2000) have been proposed as possible cell popula-
tions generating HFO. Supporters of the interneuron hypothesis
propose that the late HFO represent the activities of com-
bined vertically and horizontally oriented GABAergic inhibitory
interneurons in somatosensory cortex (Hashimoto et al., 1996;
Ozaki et al., 2001; Ozaki and Hashimoto, 2005, 2011). They rely
on the divergence in the orientation of the dipoles between HFO
source and underlying N20 source (Ozaki et al., 2001; Ozaki and
Hashimoto, 2011).
Previously, the variability of wave shapes of SEPs in chronic
schizophrenic patients was described as a high early and low
late stability of amplitudes (Shagass et al., 1977; Lehtonen, 1981)
probably depending on the acuity of the disease. Norra et al.
(2004) reported alterations of the thalamocortical somatosen-
sory signal processing in schizophrenia. To our knowledge, no
such study exists for bipolar disorder or for subjects at risk of
schizophrenia or bipolar disorder yet.
This non-invasive electrophysiological study aims to explore
potential differences in early sensory filtering in at risk probands
for schizophrenia and bipolar disorder by analyzing low-
frequency responses and HFOs in relationship to the symptoms.
We hypothesize that alterations of signal processing observed in
clinical populations are observable also at the at-risk level in a
way comparable to the findings of Norra et al. (2004). In that
study later HFOs in subjects with schizophrenia and higher N20
dipole source strengths were reported. The later HFOs are inter-
preted as epiphenomena of poorer thalamocortical filtering and
the larger N20 as epiphenomena of a larger signal strength follow-
ing this poorer filtering. The analysis was performed with regards
to cannabis use as it is considered to increase the risk of devel-
oping psychosis (Kawohl and Rössler, 2008; Roser et al., 2010;
Gururajan et al., 2012).
MATERIAL AND METHODS
SUBJECTS
Subjects at risk were recruited in the Canton of Zurich,
Switzerland, in the context of a prospective longitudinal multi-
level-approach (psychopathology, neuropsychology, electrophys-
iology, sociophysiology, genetic, MRI) on early recognition of
psychoses within the framework of the “Zurich Program for
Sustainable Development of Mental Health Services” (Zürcher
Impulsprogramm zur nachhaltigen Entwicklung der Psychiatrie,
i.e., ZInEP, http://www.zinep.ch). The present study analyses data
from the first step of assessment in a cross-sectional design.
The recruitment of subjects was carried out through a study
website, flyers and newspaper advertising, or the subjects were
referred to the study center by general practitioners, school psy-
chologists, counseling services, psychiatrists, or psychologists.
Following an initial screening, diagnostic interviews were admin-
istered face-to-face. After complete description of the study to
participants, written informed consent was obtained; in case of
minors including the written informed consent of their parents.
The study was approved by the regional ethics committee of the
canton of Zurich and was in accordance with the Declaration
of Helsinki. For assessment of psychopathological symptoms all
participants of the study were examined carefully by clinically
skilled psychiatrists and psychologists. As inclusion criterion for
our study, subjects had to fulfill at least one of the following three
criteria:
(1) High-risk (HR) status for psychosis assessed by the adult
(Schultze-Lutter et al., 2007) or children-youth (Schultze-
Lutter and Koch, 2010) version of the Schizophrenia
Proneness Interview (SPI-A/SPI-CY), with at least one
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cognitive-perceptive (COPER) basic symptom or at least two
cognitive disturbances (COGDIS) basic symptoms.
(2) Ultra-high-risk (UHR) status for psychosis as rated by
the Structured Interview for Prodromal Syndromes (SIPS)
(McGlashan et al., 2001) with at least one attenuated psy-
chotic symptom, or at least one brief limited intermittent
psychotic symptom, or a positive state-trait criterion (reduc-
tion in global assessment of functioning of >30% in the
past year, plus either schizotypal personality disorder or first
degree relative with psychosis).
(3) At-risk state for bipolar disorder (at-risk-bip) was defined
by a score ≥14 in the Hypomania Checklist (Angst et al.,
2005), or a score of ≥12 on the Hamilton Depression Scale
(Williams, 1988), or a first degree relative with a bipolar dis-
order and a reduction in global assessment of functioning
of >30% in the past year.
The division intoHR andUHR subjects within the schizophrenia-
risk group was made with the aim to distinguish between subjects
with a more general risk (HR) and subjects with imminent risk
(UHR) of transition to manifest schizophrenia (Klosterkötter
et al., 2011; Fusar-Poli et al., 2013).
In addition to the scales for early recognition, the PANSS
(Kay et al., 1987) was conducted to measure also the more
pronounced psychotic symptoms. PANSS scores are given in
Table 1. Exclusion criteria for study participation were manifest
schizophrenic, substance-induced or organic psychosis or bipo-
lar disorder, current substance or alcohol dependence; age below
13 or above 35 years; or low intellectual abilities with IQ < 80.
Among the 185 subjects with available HF-SEP data, 82 fulfilled
the UHR criteria for psychosis (UHR group), 73 the HR criteria
(HR group) and 30 only the at-risk for bipolar disorder criteria
(at-risk-Bip group). Several subjects met two or all of the three
inclusion criteria. In the UHR group, 71 also met the HR crite-
ria and 8 the at-risk-Bip criteria. From the HR group, 69 subjects
fulfilled also the at-risk-Bip criteria. Twenty eight subjects were
removed from the analysis (9 from the UHR group, 14 from the
HR group and 5 from the at-risk-Bip group) due to reduced data
quality (10 subjects without signal, 18 subjects with low-level sig-
nal but without high-level signal). From the 157 subjects in a risk
status included in analysis, 43 subjects met the three inclusion
criteria, 71 subjects met two of the inclusion criteria (5 UHR and
at-risk-Bip, 18 UHR and HR, 48 HR and at-risk-Bip) and 43 sub-
jects met only one inclusion criterion (7 UHR, 11 HR and 25
at-risk-Bip). The at-risk-Bip group did not include HR or UHR
subjects, the HR group no UHR subjects.
Fifty healthy controls (HC), matched regarding age and gender
rates to the whole at-risk group, were enrolled in the study, 45 of
them with available HF-SEP data. The presence of any mental ill-
ness was excluded using the Mini-International Neuropsychiatric
Interview (Sheehan et al., 1998). The UHR-group was signif-
icantly younger than the other groups (p < 0.005). The HC
group and at-risk-Bip group had a significant higher IQ than
the HR [t(73) = 2.00, resp. t(96) = 2.23, p < 0.05] and the UHR
group [t(88) = 2.29, resp. t(111) = 2.79, p < 0.05]. There were
no group difference in sex and handedness. When attenuated
psychotic symptoms were associated with distress, some subjects
were treated with antipsychotic medication. Antipsychotic
medication status is given in chlorpromazine-equivalent
(CPZe) dosage (Andreasen et al., 2010). Details are shown in
Table 1.
SEP RECORDING
Subjects were requested to sit in a comfortable chair with their
eyes open, in a quiet laboratory. They were instructed to relax
and to avoid movements throughout the stimulus presentation
sequence and the recording. Electrical transcutaneous stimula-
tion was performed with two electrodes over the median nerve on
the wrist of the dominant hand. Single constant-current square
wave pulses of a duration of 0.2 s were delivered with an inten-
sity of 4mA above individual motor threshold (max. 20mA) and
a stimulus rate of 6Hz. To preserve a stable level of vigilance
during stimulus presentation, participants were asked to watch a
“Mr. Bean” movie without sound. EEG data were recorded using
a BrainAmp amplifier and the Brain Vision Recorder software
(both Brain Products GmbH, Munich, Germany). Electrodes
were applied to the scalp using carefully positioned nylon caps
[BrainCap with 32 channels (Easycap, Herrsching-Breitbrunn,
Germany)] in accordance with the international 10/20 sys-
tem. Scalp electrode impedances were kept below 10 k. EEG
Channels were referenced to FCz. Data were collected with a
sampling rate of 2500Hz.
Table 1 | Sample descriptive.
n Sex Age Handedness Medication IQ* PANSSc
w m Mean (sd) Range Right Left CPZea n ADb n Positive Negative General
(mean) mean mean mean
HC 45 19 26 20.7 (5.3) 13–35 39 6 0 0 109.1 – – –
Bip 25 10 15 23.5 (6.3) 14–35 23 2 2 (122.3) 9 109.4 8.8 11.7 26.5
HR 59 25 34 23.4 (5.2) 14–34 53 6 10 (115.0) 18 103.7 9.9 12.0 27.6
UHR 73 28 45 18.7 (4.8) 13–35 62 11 19 (184.6) 14 101.9 14.8 15.9 34.3
*IQ was estimated from MWT-B for subjects >18 years and from LPS and HAWIK for subjects <18 years.
aChlorpromazine equivalent.
bAntidepressants: HC, healthy controls; Bip, at-risk-bipolar; HR, high-risk; UHR, ultra-high-risk.
cPositive and negative symptom scale.
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DATA ANALYSIS
Source reconstruction was performed individually for each sub-
ject with dipole source analysis applying the Brain Electrical
Source Analysis (BESA 5.1.8: MEGIS, Munich, Germany; www.
besa.de) software. Artifact-free sweeps containing 250 addresses
over a period of 100ms, from 20ms before to 80ms after the
stimulation were included in the analysis. Single dipole sources
were fitted for each subject for a time period between 14 and
24ms. Although the optimal solution to model all the differ-
ent early SEPs needs a complex source configuration with at
least three dipoles (Buchner et al., 1995), for our aim to demon-
strate differences in signal composition between the subgroups an
approach with one dipole was considered to be sufficient. This is
in accordance with other studies such as Norra et al. (2004) or
Waberski et al. (2004). The resulting dipole waveform was digi-
tally filtered. A low-pass filter of 450Hz (12 dB/octave slope, zero
phase shift) and a high-pass filter of 40Hz (12 dB/octave slope,
zero phase shift) were used to determine latency and strength of
the low-frequency activity as estimated by dipole source analysis.
The strength of the low-frequency activity source was determined
semi-automatically (a) as the absolute value of the minimum of
the source waveform between 14 and 24ms (N20) and (b) as
the N20minus the value of the next positive peak (N20-P25).
High-frequency filtering was done with a low-pass filter turned
off and a high-pass filter of 450Hz (12 dB/octave slope, zero
phase shift) to extract HFOs. For early HFO-components peaking
before the maximum of N20, latencies of the negative oscillatory
maxima and maximum peak-to-peak amplitudes were measured.
Latencies and amplitudes of the late HFO subcomponents were
computed in the same way as for the early HFO burst peak-
ing after the N20 maximum (Gobbele et al., 2003). All peaks
were plotted with the software Python (Python LanguageWebsite,
http://www.python.org) and inspected visually.
STATISTICAL ANALYSIS
All statistical tests were performed using the IBM SPSS Statistic
20.0 package for Windows (IBM Corp.). Visual inspection of his-
togram revealed normal distribution of data. The Kolmogorov–
Smirnov-Test was omitted because of the large sample size.
Levene-Test revealed that the variances were roughly equal, so that
we used parametrical tests. Group comparisons were performed
with Student’s t-test or ANOVA and corrected for multiple
comparisons with Games-Howell post-hoc test. Correlation coef-
ficients for variables of SEPs and clinical psychopathological
scores were calculated with Pearson’s r. Statistical significance was
taken as p < 0.05. Effect sizes (ES) were reported (Cohen’s d,
while d = 0.3 indicates a small, d = 0.5 a medium and d = 0.8
a large effect; and r-values, r = 0.1 indicating a small, r = 0.3
a medium and r = 0.5 a large effect).
RESULTS
SEP PARAMETERS: GROUP COMPARISONS
Group differences were found for the strength of the N20 source
as well as for amplitudes of the maxima of the early and of
the late part of the HFO. Details are given in Table 2. Post-
hoc tests revealed that, compared to the at-risk-bip group, N20
source activity were significantly lower in the HR [3.74, 95%
CI (0.03–7.45), p < 0.05] and the UHR groups (3.90, 95% CI
(0.26–7.54), p < 0.05). Furthermore, compared to the at-risk-bip
group, amplitudes were significantly lower in the HR group for
the early part of HFO [0.67, 95% CI (0.13–1.22), p < 0.05] and
the late part of HFO [0.61, 95% CI (0.05–1.16), p < 0.05]. The
HC group did not differ significantly from the risk groups.
SEP PARAMETERS: GROUP COMPARISONS WITH REGARD TO
CANNABIS USE
Subjects reporting several times a week, weekly and monthly
use of cannabis were grouped together (because of small group
sizes in the respective categories) to obtain the group “users,” as
opposed to the group “non-users.” Individuals reporting rare use
(less frequently than monthly) were removed from the compari-
son. The information about cannabis use of 37 subjects in the risk
groups was not available. Details are given in Table 3. During SEP
recordings the subjects did not experience acute cannabis effects,
because they had not used cannabis on the day of examination.
None of the subjects suffer from cannabis dependence, thus no
withdrawal symptoms were observed during testing.
Comparison of source activity: cannabis users vs. cannabis
non-users
In the at-risk-bip group, cannabis users showed slightly lower
N20 strength than non-users, but this difference did not reach
Table 2 | SEP parameters for the different groups.
HC n = 45 Bip n = 25 HR n = 59 UHR n = 73 F a ES (r) rb
N20 Strengthb −9.67 (4.4) −12.42 (6.3) −8.68 (4.2) −8.53 (4.0) 5.23*** 0.86 0.74
Latencyc 19.06 (1.5) 19.02 (1.5) 19.67 (1.3) 19.41 (1.3) 2.23
N20-P25 Strengthb 24.42 (9.2) 26.87 (11.1) 21.35 (8.3) 21.37 (8.7) 3.30* 0.21 0.04
HFO early Amplitudeb 1.58 (0.9) 1.86 (0.9) 1.19 (0.7) 1.32 (0.8) 4.91*** 0.27 0.07
Latency 17.90 (1.5) 18.05 (1.0) 18.27 (1.5) 18.08 (1.4) 0.60
HFO late Amplitudeb 1.52 (0.9) 1.78 (0.9) 1.17 (0.6) 1.24 (0.7) 4.58*** 0.26 0.07
Latency 19.88 (1.7) 19.86 (0.9) 19.97 (3.0) 20.40 (1.4) 0.87
ap < 0.05*, p < 0.005***.
bin nAm.
c in ms. HC, healthy controls; Bip, at-risk-bipolar; HR, high-risk; UHR, ultra-high-risk; ES, effect size.
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Table 3 | Cannabis-users vs. non-users split by group.
HC Bip HR UHR Total
n = 45 n = 25 n = 59 n = 73 n = 202
Cannabis users N 3 4 13 12 32
Cannabis non-users N 35 11 32 30 108
Missing data N 6 9 22 37
Rare cannabis use* N 7 4 5 9 25
*Was not included in the analysis; HC, healthy controls; Bip, at-risk-bipolar; HR,
high-risk; UHR, ultra-high-risk.
significance—but note the small sample size of users in this
group (n = 4). Contrary to this, in both groups at risk for
developing schizophrenia, cannabis users showed higher N20-
P25 peak-to-peak source strength than non-users, in the HR
group [t(43) = 3.60, p < 0.005, d = 1.21], and the UHR group
[t(14.3) = 2.48, p < 0.05, d = 0.87]. Amplitudes of the high-
frequency range were also higher in cannabis users than in non-
users, but reached significance only for the late part of HFO in the
UHR group [t(38) = 3.06, p < 0.005, d = 1.12]. However, SEP
source activity of cannabis non-users in the HC group did not dif-
fer significantly from those of cannabis users in the HR and UHR
groups. Differences users vs. non-users in the HC group were not
calculated because of only n = 3 cannabis users in this group. For
details, see Figure 1.
Group comparisons among cannabis non-users
Among cannabis non-users, there were significant age dif-
ferences between the groups [F(3,104) = 8.72, p < 0.001], but
the groups did not differ in sex. The HC group and the
UHR group were significantly younger than both the at-risk-
bip [t(44) = −3.51, resp. t(39) = −4.90, p < 0.005] and the HR
groups [t(65) = −2.73, resp. t(60) = −3.66, p < 0.01]. Age did
not correlate with dipole strengths, but correlated positively with
the latencies of N20 (r = 0.201, p < 0.05) and of the early part
of HFO (r = 0.199, p < 0.05) over the whole group of cannabis
non-users. Antipsychotic medication estimated by CPZe dose
(n = 31) did not correlate significantly with SEP parameters. In
the UHR group however, subjects taking antipsychotic medica-
tion had lower early HFO amplitudes than those who did not take
any medication [t(48.2) = 3.20, p < 0.005].
There was a significant effect of group on the N20 dipole
strength [F(3,104) = 4.27, p < 0.010, r = 0.33] and on the N20-
P25 peak-to-peak strength [F(3,104) = 7.56, p < 0.001, r = 0.42].
Post-hoc tests revealed that, compared to the HC group, N20
strengths resp. N20-P25 peak-to-peak strength were significantly
lower in the HR [2.84, 95% CI (0.04–5.64), p < 0.05 resp. 7.46,
95% CI (0.2.25–12.68), p < 0.005] and the UHR groups [2.96,
95% CI (0.44–5.48), p < 0.05, resp. 7.04, 95% CI (1.93–12.14),
p < 0.005]. There was neither significant difference in low-
frequency dipole strengths between HR and UHR groups nor
betweenHC and at-risk-bip groups. For an illustration of the N20
differences in the cannabis non-users groups, see grand averages
on Figure 2.
There was a significant effect of group on the maximum
peak-to-peak amplitude of the early [F(3,100) = 5.29, p < 0.005,
FIGURE 1 | Mean dipole source activity and distribution of data in the
different groups, separated into cannabis users and non-users. Note
the small sample size of cannabis users in the Bip group (n = 4) and the HC
group (n = 3). Vertical bars represent the SE.
r = 0.37] and of the late part of HFOs [F(3,101) = 4.90,
p < 0.005, r = 0.36]. Post-hoc tests revealed significantly lower
early resp. late HFO amplitudes in the HR (0.60, 95% CI (0.05–
1.14), p < 0.05 resp. 56, 95%CI (0.01–1.10), p < 0.05] and in the
UHR groups (0.55, 95% CI (0.01–1.09), p < 0.05 resp. 63, 95%
(0.09–1.17), p < 0.05] compared to the HC group. There was nei-
ther significant difference in high-frequency amplitudes between
HR andUHR groups nor betweenHC and at-risk-bip groups. For
details see Figure 1.
CORRELATIONS OF SEP-PARAMETERS WITH CLINICAL SYMPTOMS
Over the whole group of cannabis non-users in both at-risk
groups (n = 73), there was a significant negative correlation
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FIGURE 2 | Grand averages of N20 in the groups (40–450Hz) among
cannabis non-users.
between N20 and the positive symptom scale of the PANSS,
r = −0.26, p < 0.05, r2 = 0.068. This was paralleled by a trend
toward a negative correlation between N20 and the PANSS pos-
itive factor of the 5-factor model of Citrome et al. (2011),
r = −0.15, p = 0.063, r2 = 0.022, resp. Wallwork et al. (2012),
r = −0.21, p = 0.076, r2 = 0.044. N20 correlated negatively with
PANSS factor depression (Citrome et al., 2011), r = −0.29,
p < 0.05, r2 = 0.086, paralleled by a trend with the factor depres-
sion of Wallwork et al. (2012), r = −0.23, p = 0.059, r2 = 0.051.
There was a significant positive correlation between latency
of N20 and PANSS negative symptom scale, r = 0.25, p < 0.05,
r2 = 0.061, paralleled by the correlation with PANSS negative fac-
tor of the 5-factor model of Wallwork et al. (2012), r = 0.25,
p < 0.05, r2 = 0.061. N20 latency correlated with PANSS com-
posite, r = −0.27, p < 0.05, r2 = 0.075. Furthermore, dipole
strength of N20 correlated negatively with SPI-A subscale E “body
perception disturbances,” r = −0.28, p < 0.05, r2 = 0.076. The
latency of the early part of HFO correlated with SPIA sub-
scale D “disturbances in experiencing the self and surroundings,”
r = −0.29, p < 0.05, r2 = 0.086.
DISCUSSION
In this study, 25 subjects fulfilling the at-risk-bipolar criteria, 59
subjects the HR criteria for psychosis and 73 the UHR crite-
ria for psychosis were compared with 45 controls, gender- and
age-matched to the whole at-risk-group. We expected to already
observe alterations of low- and high-frequency components of
median nerve evoked SEPs in a population at risk for devel-
oping schizophrenia or bipolar disorder as these were reported
in clinical populations. To our knowledge, this is the first study
investigating SEPs in populations at risk for developing psychosis
to date.
Firstly, among the whole sample (n = 202), compared with at-
risk-bipolar subjects, a significant reduction of the mean strength
of the N20 dipole was detected in both groups of subjects
at risk for developing schizophrenia. The at-risk-bipolar group
showed actually stronger N20 source activity than the healthy
control group. Furthermore, both groups at risk for schizophre-
nia showed significant reduced amplitudes of the early and late
part of the high-frequency signal (HFO) compared to the at-risk
bipolar group. Both groups at risk for schizophrenia showed also
reduced HFO amplitudes compared to the control group, but this
difference reached significance only for the HR group. The at-risk
bipolar group did not show such a reduction.
Secondly, among cannabis non-users, the amplitudes of the
SEP parameters in the at-risk-bipolar group appeared to be sim-
ilar to those of the control group, and not enhanced as in the
cannabis users group. In both groups at risk for schizophrenia,
the amplitudes of the SEP parameters were enhanced in cannabis
users compared to non-users. Moreover, SEP amplitudes did not
differ between cannabis users of the groups at risk for schizophre-
nia and non-users of the HC group. Rentzsch et al. (2011)
reported similar effects of cannabis on MMN in schizophrenic
patients. It was proposed that delta-9-tetracannabinol produces
transient symptoms as well as behavioral and cognitive deficits
resembling those seen in schizophrenia, increasing the clini-
cal ratings of schizophrenia-like symptoms (Delisi, 2008). This
may explain the observed effect of cannabis use in the present
risk population. According to this, some subjects at risk for
schizophrenia may not have shown risk symptoms if they did not
have used cannabis. Another possible interpretation of the effects
of cannabis postulates that cannabis may exhibit neuroprotec-
tive effects counteracting a putative neurotoxic process related to
schizophrenia (Jockers-Scherubl et al., 2007; Potvin et al., 2008;
Rentzsch et al., 2011). However, another explanation could be
that risk subjects with comorbid cannabis use are less impaired
compared to subjects without substance use.
Over the whole risk group of cannabis non-users, the above
mentioned neurophysiological alterations were associated with
impediments assessed on psychopathological level. Reduced low-
frequency source activity were related to more positive symptoms
as assessed by PANSS. Longer N20 latencies were associated
with higher scores on PANSS negative and composite subscales.
Reduced N20 source activity were also observed in subjects with
more body perception disturbances (SPIA-E).
The findings of the present study are in accordance with
other findings in individuals at risk for developing schizophre-
nia. At-risk individuals for schizophrenia showed significantly
lower ERP amplitudes (P100, N170, N250) than healthy con-
trols in a recognition task of facial affect (Wolwer et al., 2011).
Sensory gating (P50 and N100) was already impaired in early
stages of schizophrenia (at-risk, truly prodromal and first episode
subjects), with most prominent impairments in chronic stages
(Brockhaus-Dumke et al., 2008). Smaller P300 amplitudes were
observed in high-risk individuals (Frommann et al., 2008). These
ERP abnormalities are similar to those previously reported in
manifest schizophrenia. Reduction of ERP amplitudes is a well-
replicated finding in schizophrenia. The P50 amplitude and audi-
tory sensory gating (McCarley et al., 1997; Adler et al., 1998),
the amplitude of early P1 visual evoked potential (Koychev et al.,
2012) as well as the amplitude of mismatch negativity (Atkinson
et al., 2012) and reorienting negativity (Rissling et al., 2012)
were shown to be diminished. Several ERPs have been discussed
as vulnerability markers for schizophrenia (Van Der Stelt and
Belger, 2007; Ladea and Prelipceanu, 2009). In contrast, neither
of these early ERP components was reduced in bipolar disorder.
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Previous studies reported N100 and P200 components to be
intact in manifest bipolar disorder (Muir et al., 1991; O’donnell
et al., 2004). Furthermore, when similar neuroanatomic alter-
ations were reported for both groups, these weremostly less severe
in bipolar disorder than in schizophrenia (Maier et al., 2006; Yu
et al., 2010).
As the amplitude reduction can be interpreted as a reduced
sensory registration (Brockhaus-Dumke et al., 2008), this data is
in line with the increasing body of evidence suggesting a gating
deficit in schizophrenia. Moreover, in contrast to bipolar disorder,
early sensory processing in schizophrenia is reduced already in
at risk subjects, adding evidence to the assumption that specific
sensory dysfunctions precede the onset of schizophrenia.
Under the assumption that late HFO represent the activities
of GABAergic inhibitory interneurons in somatosensory cortex
(Hashimoto et al., 1996; Ozaki et al., 2001; Ozaki and Hashimoto,
2005, 2011), the lower amplitudes of HFO in both schizophrenia-
risk groups could point to a GABAergic dysfunction (Hasan et al.,
2012). GABAergic interneurons provide both inhibitory and dis-
inhibitory modulation of cortical and hippocampal circuits and
contribute to the generation of oscillatory rhythms, discrimi-
native information processing and gating of sensory informa-
tion within the corticolimbic system (Benes and Berretta, 2001).
Disruption of the balance between excitation and inhibition has
been suggested to lead to gating defects that are related to cog-
nitive impairment, as observed in schizophrenia (Marin, 2012).
Glutaminergic neurons are the major excitatory pathways link-
ing the cortex, limbic systems, and thalamus, regions that have
been implicated in schizophrenia, with dysfunctional glutaminer-
gic and related dopaminergic neurotransmission (Goff and Coyle,
2001). Recently, reduced thalamic glutamate levels were reported
in people at risk for developing psychosis (Fusar-Poli et al., 2011).
Kaufman et al. (2009) found no difference in brain GABA, gluta-
mate or glutamine levels between patients with bipolar disorder
and controls.
In contrast to the present findings, a previous SEP study in
schizophrenia indicated higher N20 mean amplitude (Shagass
et al., 1977; Lehtonen, 1981; Norra et al., 2004), and later HFO
in patients compared to healthy controls (Norra et al., 2004). The
different experimental groups, i.e., risk patients in the present
sample and chronic patients in the study of Norra et al. (2004),
may have contributed to the inconsistent findings between stud-
ies. First, the duration of illness had an effect on frequency of
N20. In addition, all patients of Norra et al. (2004) were tak-
ing antipsychotic drugs before and during the study. This could
have influenced the results, as other studies reported altered EP
amplitudes (Straumanis et al., 1982; Duncan and Kaye, 1987;
Duncan et al., 1987; Ford et al., 1994) and later ERP in medicated
schizophrenic patients (Pfefferbaum et al., 1989).
Our study has methodological limitations. First, sample sizes
were unequal. But as the data were normally distributed and the
variances were roughly equal, we can assume that the power of
the F statistic was not affected. Then, the UHR group was signif-
icantly younger than the other groups. A possible explanation for
this could be given by the fact that individuals with higher risk to
develop schizophrenia may fall ill younger. However, it appears
unlikely that age did affect SEP parameters, primarily because
age did not correlate with SEP parameters. Moreover, comparable
SEP results were found for both the HR and the UHR group,
while the HR group did not differ in mean age from the other
groups. Additionally, more subjects from the UHR group were
taking antipsychotic medication, compared to the other groups.
The observed group effect might be confounded with the effect of
medication. Another confounding effect may be that of alcohol
and tobacco, as several subjects in a risk status for psychoses can
be prone to use these substances. Finally, the correlations were not
corrected for multiple testing, and given that the effect sizes are
ranging from small to medium (r = 0.15–0.29) resp. the percent-
age of variance accounted for by the predictor variables is quite
low (2.2–8.6%), they have to be interpreted with caution. At last,
the present cross-sectional analysis limits the explanatory power
of the data. Further longitudinal analysis of data from ZInEP is
needed. Furthermore, the used method of dipole source analysis
is not suitable for clinical practice. Whether a simple one-channel
information would lead to comparable results requires further
experimentation.
In summary, the findings of the present study suggest that
the risk for schizophrenia, in contrast to bipolar disorder, may
involve an impairment of early cerebral somatosensory process-
ing. Neurophysiologic alterations in schizophrenia may precede
the onset of initial psychotic episode and could therefore serve
as indicator of vulnerability for developing schizophrenia. To our
knowledge, this study is the largest investigation of somatosensory
evoked potentials published to date, and the first in populations
at risk for developing psychosis. The heterogeneity among studies
and the lack of SEP studies comparing schizophrenia and bipolar
disorder as well as the sparse studies comparing these populations
on the risk level limit definitive conclusions from the literature
to date.
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